Meropenem-vaborbactam
Based on 1 Customer Validation
Meropenem-vaborbactam (Carbavance) is a Carbapenem Antibiotic and Boronic acid-based beta-lactamase inhibitor, is a fixed-dose combination product with potent in vitro activity against Enterobacteriaceae that are Klebsiella pneumoniae carbapenemase producers. Meropenem-vaborbactam exhibits activity against Pseudomonas aeruginosa isolates , with an MIC50 of 0.5 μg/mL and an MIC90 of 8 μg/mL.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.91%
- CAS 番号: 2031124-72-6
- 分子式: C29H41BN4O10S2
- 分子量:680.60
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
生物活性
Meropenem-vaborbactam (≤1-≤2 μg/mL) potently inhibits Enterobacteriaceae isolates, with an MIC50 of ≤0.015 μg/mL and an MIC90 of 0.06 μg/mL; 99.1% and 99.3% of the isolates are inhibited at concentrations of ≤1 μg/mL and ≤2 μg/mL, respectively[1].
Meropenem-vaborbactam exhibits activity against isolates of Pseudomonas aeruginosa, with an MIC50 of 0.5 μg/mL and an MIC90 of 8 μg/mL[1].
Meropenem-vaborbactam exhibits potent in vitro activity against 991 KPC-producing Enterobacterales strains, with an MIC50 of 0.06 mg/L and an MIC90 of 1 mg/L[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:neutropenic mice[2]
-
Dosage:meropenem 2 g; vaborbactam 8 mg/L (as combination)
-
Administration:3-hour infusion; every 8 hours
-
Result:Achieved bacteriostasis at an fAUC:MIC ratio of 9.
Achieved a 1-log10 kill against KPC-producing Enterobacteriaceae at an fAUC:MIC ratio of 38.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 2031124-72-6
-
性状 Solid
-
分子量 680.60
-
分子式 C29H41BN4O10S2
-
Color Light yellow to yellow
-
SMILES
OC(C1=C(S[C@H]2C[C@H](NC2)C(N(C)C)=O)[C@H](C)[C@@]([C@@]3([H])[C@H](O)C)([H])N1C3=O)=O.O=C(CC4=CC=CS4)N[C@@H]5B(O[C@@H](CC5)CC(O)=O)O
-
別名
Carbavance
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
DMSO : 10 mg/mL (14.69 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Castanheira M, et al. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00567-17. Published 2017 Aug 24. [Content Brief]
[2]. Petty LA, et al. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2018 Sep 12;11:1461-1472. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4693 mL | 7.3465 mL | 14.6929 mL | 36.7323 mL |
| 5 mM | 0.2939 mL | 1.4693 mL | 2.9386 mL | 7.3465 mL | |
| 10 mM | 0.1469 mL | 0.7346 mL | 1.4693 mL | 3.6732 mL |
- Meropenem-vaborbactam
- 2031124-72-6
- Carbavance
- Antibiotic
- Bacterial
- Beta-lactamase
- KPC serine carbapenemase
- complicated urinary tract infection
- Ambler class A serine beta-lactamases
- penicillin-binding proteins
- Enterobacteriaceae
- Pseudomonas aeruginosa
- Stenotrophomonas maltophilia
- Ambler class C serine beta-lactamases
- Acinetobacter spp.
- gram-negative bacterial infections
- Inhibitor
- inhibitor
- inhibit